Cagrilintide: Weight Loss & Dosage

Cagrilintide is a synthetic version of amylin, a hormone your body produces alongside insulin from the beta cells of the pancreas. Natural amylin is released every time you eat. It signals fullness to your brain, slows digestion, and suppresses glucagon (which lowers blood sugar).

Natural amylin has a half-life of about 13 minutes. Cagrilintide is engineered to last approximately 7 days, making once-weekly injection possible. It activates both the amylin receptor (AMY1/AMY3) and the calcitonin receptor (CTR), which is why it is classified as a dual amylin and calcitonin receptor agonist.

The critical distinction from GLP-1 drugs: cagrilintide works through a different brain pathway. Semaglutide and tirzepatide suppress appetite primarily through GLP-1 receptors in the gut and brainstem. Cagrilintide acts on the hypothalamus through amylin receptors, affecting both homeostatic hunger (your body's energy balance system) and hedonic hunger (the reward-driven desire to eat). This dual-pathway action is why the combination outperforms either drug alone.

When cagrilintide binds to amylin receptors in the area postrema and hypothalamus, three things happen.

1. 1.Appetite suppression through satiety centers. The hypothalamus receives stronger "full" signals after eating, reducing both how much you eat and how often you think about food.
2. 2.Slowed gastric emptying. Food moves through your stomach more slowly, extending the feeling of fullness after meals. This overlaps with GLP-1's mechanism but acts through a separate receptor pathway.
3. 3.Glucagon suppression. By reducing postprandial glucagon release, cagrilintide helps prevent blood sugar spikes after meals. This is particularly relevant for patients with type 2 diabetes.

The hedonic hunger component is notable. Most GLP-1 drugs primarily reduce homeostatic hunger (the physical sensation). Cagrilintide also targets the reward pathways that drive cravings for specific foods, particularly high-calorie options. Early research suggests this may explain why CagriSema patients report less food obsession than patients on GLP-1 drugs alone.

The standard cagrilintide titration follows the Phase 3 REDEFINE trial protocol. Dose escalation occurs every 4 weeks to minimize gastrointestinal side effects.

An alternative rapid titration schedule used in some trials starts at 0.6 mg and escalates every 2 weeks to reach a 4.5 mg maintenance dose.

When used as CagriSema, the semaglutide component follows its own titration schedule simultaneously. The semaglutide dose in CagriSema reaches 2.4 mg (the same as Wegovy's maintenance dose). Both components are administered as separate injections on the same day.

For context on semaglutide dosing, see our semaglutide dosage chart. For reconstitution guidance, see our semaglutide mixing guide.

Novo Nordisk has tested cagrilintide through the REDEFINE clinical trial program.

CagriSema's competitive position is nuanced. It matches tirzepatide on weight loss but uses a fundamentally different mechanism. This matters because patients who do not respond well to GLP-1 + GIP (tirzepatide's mechanism) may respond to GLP-1 + amylin (CagriSema's mechanism). Having drugs with different mechanisms gives physicians more options.

CagriSema may also preserve more lean muscle mass during weight loss compared to GLP-1-only drugs, though this requires further study. The amylin pathway's effect on body composition is an active research area.

For detailed comparisons of available drugs, see our retatrutide vs tirzepatide comparison and our complete retatrutide guide.

Cagrilintide and CagriSema side effects follow the same pattern as other injectable weight loss drugs. GI events are the most common and are dose-dependent.

Most GI side effects are classified as mild and transient. They peak during dose escalation (the first 16 weeks) and improve significantly at stable maintenance doses. The injection site reaction rate is higher for CagriSema than semaglutide alone, likely because two separate injections are required.

Serious adverse events were rare in the REDEFINE trials. Acute pancreatitis, gallbladder events, and kidney events occurred at rates similar to semaglutide monotherapy.

For managing similar side effects with available GLP-1 medications, see our guides on semaglutide nausea and tirzepatide constipation.

Novo Nordisk has filed a New Drug Application (NDA) with the FDA for CagriSema. The timeline depends on the FDA review cycle, but approval is possible in late 2026 or 2027.

If approved, CagriSema would be the first combination obesity drug targeting both amylin and GLP-1 pathways. It would compete directly with tirzepatide (Zepbound) and provide an alternative mechanism for patients who do not achieve adequate results with existing GLP-1 drugs.

Pricing is not yet announced, but given Novo Nordisk's pricing for Wegovy ($1,349/month list price), CagriSema will likely carry a premium. Insurance coverage negotiations will be a major factor in real-world accessibility.

For patients seeking treatment now, semaglutide and tirzepatide are the FDA-approved options. Use our semaglutide dosage calculator or tirzepatide dosage calculator for dosing information.